Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents

Seminars in Ophthalmology

Volumn 28, Issue 3, 2013, Pages 126-130

  Abedi, Gelareh ^a   Adelman, Ron A ^b   Salim, Sarwat ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Anti vascular endothelial growth factor; Bevacizumab (Avastin); Glaucoma; Intraocular pressure; Intravitreal ranibizumab (Lucentis)

Indexed keywords

BEVACIZUMAB; CYANOCOBALAMIN; PEGAPTANIB; RANIBIZUMAB; SILICONE OIL; VASCULOTROPIN INHIBITOR;

AQUEOUS HUMOR FLOW; CLINICAL FEATURE; DRUG INDICATION; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NEOVASCULAR GLAUCOMA; OPTIC NERVE; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; OCULAR HYPERTENSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878285703     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2013.771195     Document Type: Review

References (32)

1. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167: 1451-1459. (Pubitemid 41541430)
2. Peters S, Heiduschka P, Julien S, et al. Ultrastructrual findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143: 995-1002.
3. Manousaridis K, Talks J. Macular ischemia: A contraindication for anti-VEGF treatment in retinal vascular disease. Br J Ophthalmol 2012;96: 179-184.
4. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular agerelated macular degeneration. Retina 2006;25(8): 859-870. (Pubitemid 44547437)
5. Wehrli SJ, Tawse K, Levin MH. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 2012;32(7): 1295-301.
6. Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95: 1111-1114.
7. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30: 887-892.
8. Liu L, Ammar DA, Ross LA, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: Effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52: 1023-1034.
9. Kim JE, Mantravad AV, Hur EY, et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146: 930-934.
10. Higashide T, Murotani E, Saito Y, et al. Adverse events associated with intravitreal injection of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2012;250: 603-610.
11. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 2009;23: 181-185.
12. Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18: 658-661.
13. Hariprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 2006;141: 200-201. (Pubitemid 43016199)
14. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007;27: 1044-1047. (Pubitemid 350304005)
15. Semoun O, Blumen Ohana E, de Preobrajensky N, et al. Acute angle-closure complicating an intravitreal injection of bevacizumab. J Fr Ophthalmol 2009; 32(1):e1-4.
16. Martel JN, Han Y, Lin SC. Severe intraocular pressure fluctuation after intravitreal anti-vascular endothelial growth factor injection. Ophthalmic Surg Lasers Imaging 2011;13:e100-2.
17. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration (MARINA). N Engl J Med 2006;355: 1419-1431. (Pubitemid 44511557)
18. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration (ANCHOR). N Engl J Med 2006;355: 1432-1444. (Pubitemid 44511558)
19. D'Amico DJ, Masonson HN, et al. Pegaptanib sodium for neovascular age-related macular degeneration: Twoyear safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113: 992-1001.
20. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246: 81-87. (Pubitemid 350167096)
21. Bakri SJ, McCannel CA, Edwards AO, et al. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246: 955-958.
22. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: An unreported complication. Eye 2007;21(12): 1541.
23. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40: 293-295.
24. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26: 105-110.
25. Choi, DY, Ortube MC, McCannell CA. Sustained elevated intraocular pressures after intravitreal injections of Bevacizumab, Ranibizumab and Pegaptanib. Retina 2011; 31: 1028-1035.
26. Bakri SJ, Moshfeghi DM, Rundle A, et al. IOP in eyes treated with monthly ranibizumab: A post hoc analysis of data from the MARINA and ANCHOR trials. Presented as a scientific paper at the AAO Annual Meeting, October 15, 2010, Chicago, IL, USA.
27. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21: 241-247.
28. Hoang QV, Mendonca LS, Della Torre KE. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119: 321-326.
29. Tranos P, Bhar G, Little B. Postoperative intraocular pressure spikes: The need to treat. Eye 2004;18(7): 673-679. (Pubitemid 39117417)
30. Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol 2012;23: 105-110.
31. Kotliar K, Maier M, Bauer S, et al. Effect of intravitreal injections and volume changes on intraocular pressure: Clinical results and biomechanical model. Acta Ophthalmol Scand 2007;85: 777-781. (Pubitemid 47616796)
32. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42: 807-811.